Silver doesn't think further action by the FDA is needed. "I don't think the drug needs to be looked at for patients who are currently being treated in this country, but it certainly will give pause to the way studies are being designed to look at the neuroprotective effects of these drugs," he said.
More information
For more information on ESA's, visit the U.S. Food and Drug Administration.
Copyright © 2011 HealthDay. All rights reserved.
